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Background: Data on the association between influenza and tuberculosis are limited. We describe the characteristics of
patients with laboratory-confirmed tuberculosis, laboratory-confirmed influenza and tuberculosis-influenza co-infection.
Methods: Patients hospitalized with severe respiratory illness (acute and chronic) were enrolled prospectively in four
provinces in South Africa. Naso/oropharyngeal specimens were tested for influenza virus by real time reverse
transcriptase polymerase chain reaction. Tuberculosis testing was conducted as part of clinical management.
Results: From June 2010 through December 2011, 8032 patients were enrolled and influenza testing was conducted
on 7863 (98%). Influenza virus was detected in 765 (10%) patients. Among 2959 patients with tuberculosis and
influenza results, 2227 (75%) were negative for both pathogens, 423 (14%) were positive for tuberculosis alone,
275 (9%) were positive for influenza alone and 34 (1%) had influenza and tuberculosis co-infection. On multivariable
analysis amongst individuals with symptoms for ≥7 days, tuberculosis influenza co-infection was associated with
increased risk of death, (adjusted relative risk ratio (aRRR) (6.1, 95% confidence interval (CI) 1.6-23.4), as compared
to tuberculosis only infection. This association was not observed in individuals with symptoms for <7 days
(aRRR.0.8, 95% CI 0.1-7.0).
Conclusion: Tuberculosis and influenza co-infection compared to tuberculosis single infection was associated with
increased risk of death in individuals with symptoms ≥7 days. The potential public health impact of influenza
vaccination among persons with laboratory-confirmed tuberculosis should be explored.
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Despite the availability of efficacious treatment, tubercu-
losis remains the second most common cause of infectious
disease–related deaths worldwide, after human immuno-
deficiency virus (HIV) and acquired immune deficiency
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HIV infection is an important risk factor for tuberculosis,
and HIV-infected individuals have a 20 times greater risk
of developing tuberculosis as compared to HIV-uninfected
individuals [3]. In South Africa, there were an estimated
390,000 incident cases of tuberculosis in 2011 and 65%
were co-infected with HIV [1].
Similarly, despite the availability of effective vaccines,
influenza virus infection causes substantial annual morbid-
ity and mortality worldwide and in South Africa [4-6].
Globally, it is estimated that influenza epidemics result in
three to five million cases of severe illness, and aboutThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Walaza et al. BMC Infectious Diseases  (2015) 15:26 Page 2 of 13250,000-500,000 deaths annually [4]. In 2010 an estimated
12 million episodes of severe and 3 million episodes of
very severe acute lower respiratory tract infection resulted
in hospital admissions in children <5 years worldwide [5].
A number of risk factors are described for severe outcomes
among patients with influenza; these include extremes
of age, chronic underlying diseases, pregnancy and
immune-suppression [6]. HIV-infected individuals have
an increased risk of influenza-associated hospitalisations
and mortality [7].
While chronic lung diseases are a known risk factor
for severe outcome due to influenza infection, there are
few published data on the association between influenza
and tuberculosis. Review of data from the 1918 influenza
pandemic suggests that individuals with tuberculosis had
a disproportionately higher mortality than the general popu-
lation [8,9] and that underlying tuberculosis infection may
have contributed to the elevated mortality observed in
young adults [8,10]. There is little information about
the interaction between seasonal or pandemic influenza
and tuberculosis in recent years. In South Africa, 10%
of cases that died during the 2009 A(H1N1)pdm09 pan-
demic were co-infected with tuberculosis [11]. In South
Korea, concurrent tuberculosis and influenza A(H1N1)
pdm09 infection was reported in 7 immunocompetent
patients, none resulting in fatal outcome [12].
We describe the epidemiological and clinical characteris-
tics of patients admitted with laboratory-confirmed tuber-
culosis, influenza and tuberculosis-influenza co-infection
among patients hospitalized with severe respiratory illness




We conducted prospective hospital-based active surveillance
for Severe Acute Respiratory Illness (SARI) surveillance
at 6 public hospitals in 4 surveillance sites situated across
the country: Chris Hani Baragwanath Academic Hospital
(CHBAH), Gauteng Province; Edendale Hospital, KwaZulu-
Natal Province; the two hospitals of the Klerksdorp–
Tshepong Hospital Complex (KTHC), Northwest Province;
and Mapulaneng and Matikwana Hospitals, Mpumalanga
Province [13]. At each sentinel hospital trained surveillance
officers screened all admitted patients for surveillance in-
clusion criteria from Monday to Friday, except at CHBAH
where adult patients were screened on 2 of every 5 days
per week because of large patient numbers.
Case definitions
A case of SARI was defined as a hospitalised individual
with onset of illness within seven days of admission meet-
ing age-specific clinical inclusion criteria. We included
children aged two days through <3 months with physician-diagnosed sepsis or acute lower respiratory tract infection
(ALRI), children aged three months through <5 years with
physician-diagnosed ALRI (including, for example bron-
chitis, bronchiolitis, pneumonia and pleural effusion) and
patients aged ≥5 years meeting a modified World Health
Organization (WHO) case definition for SARI including
sudden onset of fever (>38°C) or reported fever, cough or
sore throat, and shortness of breath or difficulty breathing
[14]. In addition expanded case definitions were applied
at three of the hospitals in two of the surveillance sites,
(Edendale Hospital and KTHC) to include individuals
meeting the above case definition but with symptoms
for >7 days and individuals with suspected or confirmed
tuberculosis; these patients were defined as having severe
chronic respiratory illness (SCRI). For this analysis severe
respiratory illness (SRI) was used to refer to all enrolled
patients i.e. patients admitted with an acute or chronic
respiratory illness.
The South African National Department of Health tu-
berculosis case definitions were modified to define sus-
pected tuberculosis [15]. A suspected tuberculosis case
in children <12 years was defined as: i) any child present-
ing with a history of exposure to an infectious tuberculosis
case or with a positive tuberculin skin test and symptoms
of tuberculosis (chronic cough, weight loss and fever) with
or without an abnormal chest x-ray suggestive of tu-
berculosis, or ii) admitted with a physician diagnosis of
tuberculosis or suspected tuberculosis, or iii) initiated
on tuberculosis treatment on admission; or iv) was on
tuberculosis treatment for <2 months at the time of admis-
sion. A suspected tuberculosis case in individuals ≥12 years
of age was defined as: i) any patient presenting with night
sweats, chronic cough, weight loss or haemoptysis lasting
for >2 weeks, or ii) had a physician diagnosis of tuber-
culosis or suspected tuberculosis, or iii) was initiated
on tuberculosis treatment on admission, or iv) was on
tuberculosis treatment for <2 months at the time of
admission.
Patients who were on tuberculosis treatment for ≥2 months
at the time of admission were not enrolled into the sur-
veillance programme as cases of suspected or confirmed
tuberculosis (because we assumed that after two months
of treatment tuberculosis was no longer the reason for
their clinical presentation). These patients were, however,
enrolled if they met the criteria for SARI. The tuberculosis
status of the enrolled patients was based on results of tu-
berculosis testing at current admission.
For this analysis, a laboratory-confirmed tuberculosis case
was defined as an individual with a positive result for
Mycobacterium tuberculosis on microscopy, culture or
polymerase chain reaction (PCR) by GeneXpert MTB/
RIF test (Cepheid, Sunnyvale, California) from the current
hospital admission or from a specimen taken within two
weeks preceding or following the admission. An influenza
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for influenza. An influenza-tuberculosis co-infection case
met criteria for both laboratory-confirmed tuberculosis
and influenza during the same admission.
Data collection
A standardized questionnaire was used to collect demo-
graphic and clinical data, medical history of the patient
and in-hospital outcome. Hospital and intensive care unit
(ICU) admission and collection of specimens for bacterial
culture, tuberculosis testing and CD4+ T-cell counts were
performed according to attending-physician discretion.
Sample collection and processing
Respiratory specimens (oropharyngeal and nasopharyngeal
swabs for patients ≥5 years of age or nasopharyngeal
aspirates for children <5 years of age), were collected and
placed in 4 ml virus transport medium. Whole blood sam-
ples were collected in EDTA-containing vacutainer tubes
within 24 hours of hospital admission for the detection of
Streptococcus pneumoniae and HIV infection.
After collection, respiratory and blood samples were
kept at 4°C at the sentinel site, and transported on ice at
least twice per week to the National Institute for Com-
municable Diseases of the National Health Laboratory
Services (NICD-NHLS) for testing.
Detection of respiratory viruses and S. pneumoniae
Respiratory samples were tested by multiplex real-time
reverse-transcription polymerase chain reaction (PCR)
(rRT-PCR) for influenza type A and B, adenovirus, entero-
virus, rhinovirus, human metapneumovirus, respiratory
syncytial virus and parainfluenza virus types 1–3 [16].
The influenza A positive specimens were subtyped using
the Centers for Disease Control and Prevention (CDC)
rRT-PCR protocol for detection and characterization of
influenza. DNA was extracted from whole blood speci-
mens using the MagNA Pure LC 2.0 instrument and DNA
Isolation kit III for bacteria (Roche, Mannheim, Germany)
and were tested for the S. pneumoniae lytA gene by a
quantitative real-time PCR [17].
Determination of HIV infection
HIV status data were obtained from two data sources.
Some patients had HIV testing requested by admitting
physicians as part of clinical care. This included HIV
enzyme-linked immunosorbent assay (ELISA) testing with
confirmation by ELISA on a second specimen for pa-
tients ≥18 months of age and qualitative HIV PCR testing for
confirmation of HIV-infection status in children <18 months
of age. In addition, for consenting patients, linked anonymous
HIV PCR testing for children <18 months of age or ELISA
for patients ≥18 months of age was performed using a driedblood spot or whole blood specimen at the NICD-NHLS
laboratory.
Determination of tuberculosis infection
Testing for M. tuberculosis, including microscopy, culture,
GeneXpert MTB/RIF test, or a combination of these, was
undertaken at the discretion of the attending-physician
and performed at the laboratory serving the hospital
where the patient presented. Specimens for tuberculosis
testing were examined by light microscopy for the pres-
ence of acid fast bacilli. Tuberculosis culture was per-
formed using the BACTEC MGIT automated culture
system (Becton Dickinson, Franklin Lakes, New Jersey).
Tuberculosis PCR was performed using the Xpert MTB/
RIF system (Cepheid, Sunnyvale, California). The GeneX-
pert MTB/RIF is an automated sample processing and
nucleic acid amplification test for detection of M.
tuberculosis and is able to detect resistance to rifampi-
cin. The National Department of Health tuberculosis
treatment guidelines recommended treatment for pa-
tients with positive smears and that patients suspected
of tuberculosis should have two specimens tested on
microscopy and if these were negative then a 3rd sample
should be tested for smear and culture [15].
Data analysis
To identify factors associated with tuberculosis testing,
tuberculosis positivity and tuberculosis-influenza co-
infection we included both potential determinants for,
as well as outcomes or characteristics of the primary
endpoints of the analysis. Univariate comparisons were
performed using logistic or multinomial regression. In
addition, we implemented three multivariable models to
identify factors associated with: (i) tuberculosis testing
among enrolled patients; (ii) tuberculosis positivity among
enrolled patients tested for tuberculosis; and (iii) tubercu-
losis single infection compared to influenza single infection
or tuberculosis-influenza co-infection. The tuberculosis
testing and positivity models were implemented using
stepwise forward selection logistic regression. Multinomial
regression was used for the comparison of tuberculosis
only, influenza only and tuberculosis-influenza co-infected
groups and this analysis was performed separately in indi-
viduals with symptoms for <7 days and ≥7 days. Multi-
nomial regression allows modelling of outcome variables
with >2 categories and relates the probability of being in
category j to the probability of being in a baseline cat-
egory. A complete set of coefficients are estimated for
each of the j levels being compared with the baseline
and the effect of each predictor in the model is mea-
sured as relative risk ratio (RRR). For this analysis, we
used the tuberculosis single infection group as the
baseline category and compared it with the influenza
single infection and tuberculosis-influenza co-infection
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firmed cases for both influenza and tuberculosis. The gen-
eral form of the multivariable multinomial model with




p Y 1ð Þ ¼ β
jð Þ
0 þ β jð Þ1 X1 þ…þ β jð Þn Xn þ ε ð1Þ
Where p(Y1) is the probability of the outcome variable
in the base category (tuberculosis single infection) and
p(Yj) is the probability of the outcome variable in the
other categories; j represents the two other categories (j = 2:
influenza single infection; and j = 3: tuberculosis-influenza
coinfection) that are compared to the base category; β jð Þ0 is
the model constant for category j; β jð Þ1 to β
jð Þ
n are coefficients
associated with predictors X1 to Xn in category j; and ε is
the error term.
The model in equation 1 was fitted to any enrolled case
with available tuberculosis and influenza results irrespect-
ive of duration of symptoms as well as separately among
individuals with acute (duration of symptoms <7 days) and
chronic (duration of symptoms ≥7 days) clinical presenta-
tion to specifically assess the clinical characteristics of indi-
viduals within these two groups. In order to allow for
direct comparison of the final multivariable models for
acute and chronic patients we elected to retain any variable
which was significant at 0.05 in either one of these



























Figure 1 Flow chart of patients enrolled into the severe respiratory ilp-value <0.2 at the univariate analysis were assessed for sig-
nificance at the multivariable analysis and statistical signifi-
cance was assessed at p < 0.05 for all models. Statistically
significant variables were retained in the multivariable
models. HIV status was retained in the multinomial
models a priori as this is a potential confounder of the
interaction between influenza and tuberculosis. Two-
way interactions were assessed by inclusion of product
terms for all variables remaining in the final additive
models. The statistical analysis was implemented using
STATA® version 12 (StataCorp, Texas, USA).
Ethics
Ethical approval for the study was obtained from the
University of the Witwatersrand, Human Research Ethics
committee (reference M081042) and the University of
KwaZulu-Natal Biomedical Research Ethics committee
(reference BF157/08). The United States Centers for
Disease Control and Prevention deemed this surveillance
not to be research and therefore this project did not need
human subjects review.
Results
Patient enrolment and testing
From June 2010 through December 2011, we enrolled
8032 patients, and influenza results were obtained from
7863 (98%) cases (Figure 1). Of these 4077 (52%) were fe-
males and 3291 (42%) were children ≤5 years. InfluenzaSRI Patients enrolled 
8032





























Not tested for influenza 
169 (2%)
lness (acute and non acute) surveillance, South Africa 2009-2011.
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type was characterized from 764 (99.8%) influenza positive
samples, including 219 (29%) influenza A(H1N1)pdm09,
195 (25%) A(H3N2) and 350 (46%) influenza B. Among
patients with available influenza results, 2959 (38%) were
tested for tuberculosis during admission. Of these, 69%
(2029) and 31% (930) met the SARI and SCRI case defini-
tions, respectively. HIV results were available for 2739
(93%) of 2959 patients with available tuberculosis results
and 1877 (69%) were HIV-infected. Among influenza
tested patients with available data <1% (6/7863) received
oseltamivir and <1% (4/7857) were vaccinated against in-
fluenza. Two percent (179/7863) of enrolled patients with
results for influenza and 2% (49/2959) of those tested for
influenza and tuberculosis were already receiving tubercu-
losis treatment at time of current admission.Factors associated with tuberculosis testing on admission
Among patients with available influenza results, on mul-
tivariable analysis factors associated with tuberculosis
testing were age ≥5 years, with the highest proportion
tested (56%, 1378/2473) in the 25–44 age group (adjusted
odds ratio (aOR) 3.5, 95% CI 3.0-4.2) as compared to
age <5 years, HIV infection (aOR 1.5, 95% CI 1.3- 1.7),
symptom duration ≥7 days (aOR 1.3, 95% CI 1.1-1.5),
hospitalisation duration >7 days (aOR 1.3, 95% CI 1.1- 1.4),
requiring oxygen therapy (aOR 1.2, 95% CI 1.0-1.3) and
antibiotic (aOR 1.9, 95% CI 1.4-2.5) or tuberculosis (aOR
1.2, 95% CI 1.0-1.4) treatment started during current
admission (Table 1). The proportion of patients tested
for tuberculosis was similar for patients testing influenza-
positive and influenza-negative and for those who died
in-hospital and those who survived.Factors associated with laboratory-diagnosed tuberculosis
Among 2959 patients with available tuberculosis and in-
fluenza results, 15% (457/2959) tested positive for tuber-
culosis on the current admission and 2% (10/457) of these
were receiving tuberculosis treatment at time of current
admission. The highest percentage testing tuberculosis
positive was in the 25–44 years age group (18%, 249/1378)
(Table 2). Of the patients testing positive for tuberculosis,
332 (73%) were positive on microscopy only. The tubercu-
losis detection rate was 10% among those with symp-
toms for <7 days and 25% among those with symptoms
for ≥7 days. Of the 457 laboratory-confirmed tuberculosis
cases, 198 (43%) and 259 (57%) met the SARI and SCRI
case definitions respectively. On multivariable analysis,
patients with laboratory-diagnosed tuberculosis were less
likely to be co-infected with S. pneumoniae (aOR 0.5, 95%
CI 0.3-0.9) and to have received oxygen therapy (aOR 0.7,
95% CI 0.5- 0.9). They were more likely to be admitted at
KTHC as compared to CHBAH (aOR 1.9, 95% CI 1.4-2.6)and to be started on tuberculosis treatment at current ad-
mission (aOR 4.6, 95% CI 3.5-6.0) (Table 2).
HIV results were available for 93% (424/457) of
tuberculosis-positive and 92% (2315/2502) of tuberculosis-
negative individuals. Of these, 335 (79%) of tuberculosis-
positive and 1542 (67%) of tuberculosis-negative indi-
viduals were HIV infected. Amongst tuberculosis-positive
patients tested for HIV, age-specific HIV prevalence were
36% (15/42), 79% (35/44), 95% (222/234), 65% (58/89),
33% (5/15) in the <5 years, 5–24 years, 25–44 years, 45–
64 years and ≥65 years age groups, respectively. Amongst
tuberculosis-negative patients tested for HIV, age-specific
HIV prevalence were 19% (78/417), 71% (147/206),
89% (966/1081), 65% (325/502) and 24% (26/109) in
the <5 years, 5–24 years, 25–44 years, 45–64 years
and ≥65 years age groups, respectively.Factors associated with tuberculosis and influenza
infection
Among the 2959 patients with available tuberculosis and
influenza results, 2227 (75%) were negative for both path-
ogens, 423 (14%) were positive for tuberculosis alone, 275
(9%) were positive for influenza alone and 34 (1%) had
influenza and tuberculosis co-infection. Tuberculosis
treatment was being received at the time of admission
for 2% (n = 10) of patients positive for tuberculosis only
and <1% (n = 2) of patients positive for influenza only.
None of the patients with influenza and tuberculosis
co-infection were on tuberculosis treatment at the time
of admission.
On multivariable analysis adjusting for age group, pa-
tients infected with influenza only compared to patients
with tuberculosis only were less likely to be HIV infected
(adjusted relative risk ratio (aRRR) 0.6, 95% CI 0.4-0.9),
to present with duration of symptoms ≥7 days (aRRR 0.3,
95% CI 0.2-0.4), to be admitted for longer than 7 days
(aRRR 0.6, 95% CI 0.4-0.9) while they were more likely to
be started on oxygen therapy (aRRR 1.9, 95% CI 1.3-2.8)
(Table 3). Patients co-infected with tuberculosis and influ-
enza compared to patients with tuberculosis only were less
likely to present with symptoms ≥7 days (aRRR 0.3, 95%
CI 0.1-0.7), but were at increased risk of death (aRRR 3.1,
95% CI 1.1-10.1).
Of the 720 patients testing positive for influenza and/or
tuberculosis, 384 (53%) presented with symptom dur-
ation <7 days. Of these, 166 (43%) were positive for tu-
berculosis alone, 194 (50%) were positive for influenza
alone and 24 (6%) had tuberculosis-influenza co-
infection. Of the 336/720 (47%) patients testing posi-
tive for influenza and/or tuberculosis with symptom
duration ≥7 days, 246 (73%) were positive for tubercu-
losis alone, 81 (24%) were positive for influenza alone
and 9 (3%) had tuberculosis-influenza co-infection.
Table 1 Demographic and clinical characteristics of patients admitted with severe respiratory illness (acute and chronic), by tuberculosis testing status at four
sites in South Africa, June 2010- December 2011




P value Adjusted odds
ratios (95% CI)
P value
Age group (years) 0-4 571/3291 (17) Reference Reference
5-24 270 /587 (46) 4.05 (3.4-4.9) <0.001 3.3 (2.6-4.1) <0.001
25-44 1378/2473 (56) 5.99 (5.3-6.8) <0.001 3.5 (3.0-4.2) <0.001
45-64 611/1197 (51) 4.96 (4.3-5.7) <0.001 3.2 (2.7-3.8) <0.001
≥65 129/315 (39) 3.30 (2.6-4.2) <0.001 2.6 (2.0-3.4) <0.001
Sex Female 1664/4077 (41) Reference
Male 1295/3786 (34) 0.8 (0.7-0.8) <0.001
Site Chris Hani Baragwanath 1618/4437 (36) Reference Reference
Mapulaneng & Matikwana 144/749 (19) 0.4 (0.3-0.5) <0.001 0.4 (0.3-0.5) <0.001
Edendale 385/1156 (33) 0.9 (0.8-0.99) 0.046 0.7 (0.6-0.8) <0.001
Klerksdorp/Tshepong 812/1521 (53) 1.99 (1.8-2.2) <0.001 1.1 (0.95-1.3) 0.152
Influenza Negative 2650/7098 (37) Reference
Positive 309/765 (40) 1.1 (0.9-1.3) 0.097
HIV status Negative 862/3410 (25) Reference Reference
Positive 1877/3523 (53) 3.4 (3.0-3.7) <0.001 1.5 (1.3-1.7) <0.001
Underlying medical condition* No 2652/7041 (38) Reference
Yes 307/821 (37) 0.98 (0.85-1.14) 0.879
Duration of symptoms prior to admission (days) <7 1884/5957(32) Reference Reference
≥7 1012/1765 (57) 2.9 (2.6-3.2) <0.001 1.3 (1.1-1.5) 0.003
Concurrent invasive bacterial infection** No 653/1832 (36) Reference
Yes 24/46(52) 1.96 (1.1- 3.5) 0.023
Pneumococcal No 2435/6284 (39) Reference
Infection*** Yes 214/434 (49) 1.5 (1.3-1.9) <0.001
Receiving tuberculosis treatment at time of admission No 158/292 (54) Reference <0.001
Yes 49/179 (27) 0.3 (0.2-0.5)
Started on treatment for tuberculosis No 2301/6716 (34) Reference Reference














Table 1 Demographic and clinical characteristics of patients admitted with severe respiratory illness (acute and chronic), by tuberculosis testing status at four
sites in South Africa, June 2010- December 2011 (Continued)
Antibiotics prescribed No 77/332 (23) Reference Reference
Yes 2877/7515 (38) 2.1 (1.6-2.7) <0.001 1.9 (1.4-2.5) <0.001
Oxygen therapy No 1869/5145 (36) Reference
Yes 1086/2698 (40) 1.2 (1.1-1.3) 0.001 1.2 (1.0-1.3) 0.018
ICU admission No 2936/7772 (38) Reference
Yes 15/65 (23) 0.5 (0.3-0.9) 0.017
Duration of hospitalisation (days) ≤7 1913/5666 (34) Reference Reference
>7 1029/2143 (48) 2.9 (2.6-3.2) <0.001 1.2 (1.1-1.4) 0.002
Died No 2757/7321 (38) Reference Reference
Yes 195/509 (38) 1.02 (0.9-1.2) 0.769
HIV – human immunodeficiency virus; ICU– intensive care unit, TB-Tuberculosis.
*Underlying conditions included any of the following: Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or heart failure excluding hypertension), liver disease
(cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitus, immunocompromising conditions excluding HIV infection (organ transplant, immunosuppressive therapy,
immunoglobulin deficiency, malignancy), neurological disease (cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities were considered absent in cases for which
the medical records stated that the patient had no underlying medical condition or when there was no direct reference to that condition.
**Concurrent invasive bacterial infections were defined as a bacterial pathogen isolated from blood, cerebrospinal fluid or another sterile site from a specimen taken within 48 hours of hospitalisation; organisms
viewed as likely contaminants were excluded.
***Pneumococcal co-infection (lyt A PCR positive for Streptococcus pneumoniae on blood specimen).














Table 2 Demographic and clinical characteristics associated with laboratory-confirmed tuberculosis among patients
admitted with severe respiratory illness (acute and chronic) that were tested for tuberculosis and influenza at four





P value Adjusted odds
ratios (95% CI)
P value
Age group (years) 0-4 55/571 (10) Reference Reference
5-24 47/270 (17) 1.97 (1.3-3.0) 0.001 1.36 (0.8-2.3) 0.233
25-44 249/1378 (18) 2.1 (1.5-2.8) <0.001 1.37 (0.9-2.06) 0.120
45-64 90/611 (15) 1.6 (1.1-2.3) 0.008 1.11 (0.7-1.7) 0.628
65+ 16/129 (12) 1.3 (0.7-2.4) 0.348 0.94 (0.5-1.9) 0.872
Site Chris Hani Baragwanath 141/1618 (9) Reference Reference
Mapulaneng &
Matikwana
23/144 (16) 1.99 (1.2-3.2) 0.005 1.4 (0.8-2.3) 0.228
Edendale 49/385 (13) 1.5 (1.1-2.2) 0.016 0.9 (0.6-1.4) 0.668
Klerksdorp/Tshepong 244/812 (30) 4.5 (3.6-5.6) <0.001 1.9 (1.4-2.6) <0.001
Influenza status Negative 423/2650 (16) Reference
Positive 34/309 (11) 0.7 (0.5-0.9) 0.023
HIV status Negative 89/862 (10) Reference
Positive 335/1877 (18) 1.9 (1.5-2.4) <0.001
Underlying medical condition* No 426/2652 (16) Reference
Yes 31/307 (10) 0.6 (0.4-0.9) 0.007
Duration of symptoms prior to
admission
<7 190/1884 (10) Reference
≥7 255/1012 (25) 3.0 (2.4-3.7) <0.001
Pneumococcal co-infection on PCR** No 400/2435 (16) Reference Reference
Yes 18/214 (8) 0.5 (0.3-0.8) 0.003 0.5 (0.3-0.9) 0.016
Oxygen therapy No 337/1869 (18) Reference Reference
Yes 120/1086 (11) 0.6 (0.4-0.7) <0.001 0.7 (0.5- 0.9) 0.007
Receiving TB treatment at time of
admission
No 25/158 (16) Reference
Yes 10/49 (20) 1.4 (0.6-3.1) 0.456
Started on TB treatment No 205/2301 (9) Reference Reference
Yes 251/647 (39) 6.5 (5.2-8.0) <0.001 4.6 (3.5-6.0) <0.001
Duration of hospitalisation (days) ≤7 279/1913 (14) Reference
>7 174/1029 (17) 1.2 (0.96-1.6) 0.096
Season Summer 57/366 (15) Reference
Autumn 78/449 (17) 1.1 (0.8-1.6) 0.492
Winter 178/1027 (17) 1.1 (0.8-1.6) 0.441
Spring 144/1117 (13) 0.8 (0.6-1.1) 0.194
Died No 421/2757 (15) Reference
Yes 35/195 (18) 1.2 (0.8-1.8) 0.318
HIV – human immunodeficiency virus; ICU– Intensive Care Unit, TB-Tuberculosis, CI – confidence interval.
Analysis includes 2029 individuals with severe acute respiratory illness and 930 with severe chronic respiratory illness.
*Underlying conditions included any of the following: Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or
heart failure excluding hypertension), liver disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitus,
immunocompromising conditions excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulin deficiency, malignancy), neurological
disease (cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities were considered absent in cases for which
the medical records stated that the patient had no underlying medical condition or when there was no direct reference to that condition.
**lyt A PCR positive for Streptococcus pneumoniae on blood specimen.
Other variables that were evaluated but not presented in the table because they were not significant on univariate analysis were sex, influenza type, concurrent
bacterial infection, antibiotic prescribed on admission, admission to intensive care unit, and smoking and alcohol intake for patients ≥12 years.
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Table 3 Factors associated with influenza infection and tuberculosis-influenza co-infection compared with tuberculosis
infection only in patients admitted with severe respiratory illness (acute and chronic) and tested for tuberculosis and





Laboratory confirmed influenza Laboratory confirmed
tuberculosis-influenza
co-infection
n/N (%) RRRb ARRRc (95% CI) n/N (%) RRRb ARRRc
(95% CI)
Age group (years) 0-4 47/423 (11) 46/275 (10) Reference Reference 8/34 (22) Reference Reference
5-24 44/423 (10) 28/275 (11) 0.6 (0.3-1.2) 1.3 (0.6-2.9) 3/34 (9) 0.4 (0.1-1.6) 0.5 (0.1-2.5)
25-44 231/423 (55) 121/275 (44) 0.5 (0.3-0.8) 1.5 (0.8-2.8) 18/34 (53) 0.5 (0.2-1.2) 0.5 (0.2-1.7)
45-64 86/423 (20) 57/275 (21) 0.7 (0.4-1.1) 1.3 (0.7-2.5) 4/34 (12) 0.3 (0.1-0.9) 0.3 (0.1-2.5)
65+ 15/423 (3) 23/275 (8) 1.6 (0.7-3.4) 3.9 (1.6-9.8) 1/34 (3) 0.3 (0.04-3.4) 9.53e-07
Sex Female 247/423 (58) 176/275 (64) Reference 20/34 (59) Reference
Male 176/176 (42) 99/275 (36) 0.8 (0.6-1.1) 14/34 (41) 1.0 (0.5-1.9)
Site Chris Hani
Baragwanath
124/423 (29) 169/275 (61) Reference 17/34 (50) Reference
Mapulaneng &
Matikwana
21/423 (5) 11/275 (4) 0.4 (0.2-0.8) 2/34 (6) 0.7 (0.1-3.2)
Edendale 48/423 (11) 22/275 (8) 0.3 (0.2-0.6) 1/34 (3) 0.2 (0.01-1.2)
Klerksdorp/
Tshepong
230/423 (54) 73/275 (27) 0.2 (0.2-0.3) 14/34 (41) 0.4 (0.2-0.9)
HIV status Negative 82/392 (21) 99/257 (39) Reference Reference 7/32 (22) Reference Reference
Positive 310/392 (79) 158/257 (61 0.4 (0.3-0.6) 0.6 (0.4-0.9) 25/32 (78) 0.9 (0.4-2.3) 1.6 (0.5-4.9)
Underlying medical
conditionsd
No 394/423 (93) 240/275 (87) Reference 32/34 (94) Reference
Yes 29/423 (7) 35/275 (13) 1.98 (1.2-3.3) 2/34 (6) 0.8 (0.2-3.7)
Duration of symptoms prior
to admission
<7 166/412 (40) 194/275 (71) Reference Reference 24/33 (73) Reference Reference
≥7 246/412 (60) 81/275 (29) 0.3 (0.2-0.4) 0.4 (0.2-0.4) 9/33 (27) 0.3 (0.1-0.6) 0.3 (0.1-0.7)
Pneumoccocal co-infection
on PCRe
No 371/388 (96) 233/246 (95) Reference Reference 29/30 (97)
Yes 17/388 (4) 13/246 (5) 1.2 (0.6-2.6) 1/30 (3) 0.8 (0.1-5.8)
Oxygen therapy No 313/423 (74) 158/275 (57) Reference Reference 24/34 (71) Reference Reference
Yes 110/423 (26) 117/275 (43) 2.1 (1.5-2.9) 1.9 (1.3-2.8) 10/34 (29) 1.2 (0.5-2.6) 0.97 (0.4-2.3)
Tuberculosis treatment No 185/422 (44) 243/274 (89) Reference 20/34 (59) Reference
Yes 237/422 (56) 31/274 (11) 0.1 (0.1-0.2) 14/34 (41) 0.5 (0.3-1.1)
Hospital duration (days) ≤ 257/420 (61) 198/274 (72) Reference 22/33 (67) Reference Reference
>7 163/420 (39) 76/274 (28) 0.6 (0.4-0.8) 0.6 (0.4-0.9) 11/33 (33) 0.8 (0.4-1.7) 0.7 (0.3-1.5)
Died No 391/422 (73) 265/274 Reference Reference 30/34 (88) Reference Reference
Yes 31/422 (7) 9/274 0.4 (0.2-0.9) 0.5 (0.2-1.1) 4/34 (12) 1.7 (0.6-5.1) 3.2 (1.1-10.0)
aTuberculosis only group used as reference for multinomial model analysis (i.e. comparing influenza only to tuberculosis only and tuberculosis–influenza co-
infection to tuberculosis only group).
bUnadjusted relative risk ratio (RRR) at multivariable analysis.
cAdjusted relative risk ratio (ARRR) at multivariable analysis.
dUnderlying conditions included any of the following: Asthma, other chronic lung disease, chronic heart disease (valvular heart disease, coronary artery disease, or
heart failure excluding hypertension), liver disease (cirrhosis or liver failure), renal disease (nephrotic syndrome, chronic renal failure), diabetes mellitus,
immunocompromising conditions excluding HIV infection (organ transplant, immunosuppressive therapy, immunoglobulindeficiency, malignancy), neurological
disease (cerebrovascular accident, spinal cord injury, seizures, neuromuscular conditions) or pregnancy. Comorbidities were considered absent in cases for which
the medical records stated that the patient had no underlying medical condition or when there was no direct reference to that condition.
elyt A PCR positive for Streptococcus pneumoniae on blood specimen.
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and 14 (7–195) days in patients presenting with symp-
toms <7 days and ≥7 days respectively.
On multivariable analysis, among patients presenting
with symptoms <7 days, patients with influenza onlycompared to patients with tuberculosis only were less
likely to be admitted for >7 days (aRRR 0.4, 95% CI 0.3-
0.7). No differences were found in patients co-infected
with tuberculosis and influenza compared to patients with
tuberculosis only and there was no increased risk of death
Table 4 Factors associated with influenza infection and tuberculosis-influenza co-infection compared with tuberculosis
infection only among patients presenting with symptoms duration <7 days admitted with severe respiratory illness
and tested for tuberculosis and influenza at four sites in South Africa, June 2010-2011
Variables Laboratory confirmed
tuberculosis Referencea
Laboratory confirmed influenza Laboratory confirmed tuberculosis-influenza
co-infection
n/N (%) ARRRb P-value n/N (%) ARRRb P-value
Duration of symptoms <7 100/165 (61) 148/194 (76) Reference 6/9 (67) Reference
≥7 days 65/165 (39) 46/194 (24) 0.4 (0.3-0.7) 0.001 3/9 (33) 0.5 (0.2-1.5) 0.240
HIV status Negative 46/148 (31) 74/179 (41) Reference 5/22 (23) Reference
Positive 102/148 (69) 105/ 179 (59) 0.8 (0.5-1.2) 0.280 17/22 (77) 1.6 (0.5-4.7) 0.404
Oxygen therapy No 101/166 (61) 108/194 (56) Reference 17/24 (71) Reference
Yes 65/166 (39) 86/194 (44) 1.4 (0.9-2.3) 0.141 7/24 (29) 0.7 (0.3-2.0) 0.560
Died No 157/166 (95) 191/194 (98) 0.5(0.2-1.5) 24/24 (96) Reference
Yes 9/166 (5) 3/194 (2) 0.2 (0.04-1.2) 0.081 1/24 (4) 0.98 (0.1-8.6) 0.986
HIV – human immunodeficiency virus.
aTuberculosis only group used as reference for multinomial model analysis (i.e. comparing influenza only to tuberculosis only and tuberculosis–influenza co-infection to
tuberculosis only group).
bAdjusted relative risk ratio (ARRR) at multivariable analysis.
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0.8, 95% CI 0.1-8.6) (Table 4).
On multivariable analysis among patients presenting with
symptoms ≥7 days, patients with influenza only compared
to tuberculosis only were less likely to be HIV-infected
(aRRR 0.4, 95% CI 0.2-0.7) and more likely to receive
oxygen (aRRR 1.7, 95% CI 1.7-5.4). Patients co-infected
with tuberculosis and influenza as compared to patients
with tuberculosis only were at increased risk of death
(aRRR 5.5, 95% CI 1.2-25.3) (Table 5).
Discussion
We describe an increased risk of death associated with in-
fluenza co-infection among patients with symptoms ≥7 days
hospitalized with laboratory-confirmed tuberculosis inTable 5 Factors associated with influenza infection and tuber
infection only among patients admitted with severe respirato





Hospital duration <7 150/244 (61) 50/80 (62.5) Re
≥7 days 94/244 (39) 30/80 (37.7) 0.9
HIV status Negative 34/233 (83) 25/78 (32) Re
Positive 199/233 (17) 53/78 (68) 0.4
Oxygen therapy No 203/246 (83) 50/81 (62) Re
Yes 43/246 (17) 31/81 (38) 3.0
Died No 224/245 (91) 74/80 (92.5) Re
Yes 21/245 (9) 6/80 (7.5) 0.5
HIV – human immunodeficiency virus.
aTuberculosis only group used as reference for multinomial model analysis (i.e. com
infection to tuberculosis only group).
bAdjusted relative risk ratio (ARRR) at multivariable analysis.South Africa. Mortality was not increased in patients
co-infected with influenza and tuberculosis presenting
with a more recent symptom onset. This suggests that
influenza infection may contribute to a proportion of
the mortality burden amongst patients with tuberculosis,
in particular amongst those with a longer duration of
symptoms. Because influenza illness is considered to be an
acute infection it is possible that it is not considered as
a possible diagnosis in patients with longer duration of
symptoms. Both influenza and tuberculosis should be
considered and tested for among patients hospitalized
with pneumonia in settings with high tuberculosis preva-
lence such as South Africa. Based on the findings of this
study our surveillance programme has been amended at
two sites to include systematic testing for tuberculosisculosis-influenza co-infection compared with tuberculosis
ry illness presenting with symptoms duration ≥7 days
th Africa, June 2010- December 2011
irmed influenza Laboratory confirmed tuberculosis-influenza
co-infection
RRb P-value n/N (%) ARRRb P-value
ference 6/9 (67) Reference
9 (0.6-1.7) 0.991 3/9 (33) 0.6 (0.1-2.7) 0.520
ference 1/9 (11) Reference
(0.2-0.7) 0.002 8/9 (89) 2.2 (0.2-20.5) 0.486
ference 6/9 (67) Reference
(1.7-5.5) <0.001 3/9 (33) 2.1 (0.5-9.3) 0.315
ference 6/9 (67) Reference
4 (0.2-1.5) 0.875 3/9 (33) 5.48 (1.2-25.4) 0.029
paring influenza only to tuberculosis only and tuberculosis–influenza co-
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addition, we suggest that where possible tuberculosis
testing should be included in SARI programmes in
Sub-Saharan Africa where HIV prevalence is high.
A recent study from Thailand did not identify an in-
creased risk of severe outcomes or mortality in patients
co-infected with tuberculosis and seasonal influenza when
compared to tuberculosis and influenza single infection
[18]. The number of patients co-infected with influenza
and tuberculosis in this study were, however, small, and
patients with a more chronic presentation were not en-
rolled in the surveillance system. Similar to the findings
of our study, ecological and record review studies have
reported elevated mortality among tuberculosis-infected
individuals during previous influenza pandemics [9,10,19]
and 10% of A(H1N1)pdm09 laboratory-confirmed deaths
in South Africa in 2009, were co-infected with tubercu-
losis [11].
In patients presenting with longer duration of symptoms,
tuberculosis may have caused lung damage leading to re-
duced lung capacity and thus impairing the ability to cope
with viral infections such as influenza and potentially in-
creasing the severity of illness associated with influenza
virus infection. In addition, influenza infection impacts
on antibacterial host defenses by either increased pro-
duction of pro-inflammatory cytokines, causing cell
damage [20], or due to inadequate pro-inflammatory
chemokine response [21,22], which could increase sus-
ceptibility to tuberculosis. Lastly, immunosuppression
induced by influenza virus through production of glu-
cocorticoids [23], production of immunosuppressive cy-
tokines [20] or, suppression of T-cell immunity [24]
could trigger reactivation of latent tuberculosis and ag-
gravate pulmonary tuberculosis.
Persons with AIDS experience a significant excess mor-
tality due to influenza infection as compared to HIV-
uninfected individuals [7,25]. The relative risk of M.
tuberculosis infection among HIV-infected compared
to -uninfected persons varies between 21–37 depending
on the country’s HIV prevalence [2]. In our study, a high
proportion of patients with tuberculosis were also HIV-
infected; however the association with increased mortality
in patients co-infected with tuberculosis and influenza
virus remained statistically significant even when control-
ling for concurrent HIV infection in the model.
Despite the high prevalence of tuberculosis in South
Africa, in our study, only 37% (3018/8032) of patients
admitted with SRI were tested for tuberculosis. Even
amongst patients who were initiated on tuberculosis treat-
ment during the current admission, only 58% (656/1123)
were tested before initiation of treatment. A study con-
ducted in South Africa reported tuberculosis as the most
common cause (40%) of community acquired pneumonia
in both HIV-infected and-uninfected patients [26]. A postmortem study in patients dying in hospital found that
among patients not suspected of having tuberculosis at
time of death, 42% (40/96) were culture positive for tuber-
culosis and that pneumonia, was the leading admis-
sion diagnosis (25%) in those not suspected of tuberculosis
[27]. Only 32% of patients with symptom duration
of <7 days were tested for tuberculosis, as compared
to 57% in those with a chronic presentation, but amongst
those tested, 10% had laboratory confirmed-tuberculosis.
National guidelines for tuberculosis management advise
screening for tuberculosis in patients presenting with per-
sistent chronic symptoms (cough or fever >14 days) [28],
however results from a pooled analysis of sensitivity of
symptoms for active pulmonary tuberculosis, showed that
in studies from sub-Saharan countries, with high burden
of HIV, sensitivity of any cough was higher 62% than that
of chronic cough >2 weeks, 49% [29]. Failure to test for
tuberculosis could lead to delayed or missed diagnosis
of tuberculosis, an increase in nosocomial tuberculosis
transmission and missed opportunities to identify drug
resistance when testing with the GeneXpert assay. Be-
cause of the long duration of tuberculosis treatment and
possible associated adverse events, a microbiologic diagno-
sis of tuberculosis should be sought wherever possible
[30]. The majority of tuberculosis-positive patients in our
study were aged >5 years. Microbiological confirmation
of tuberculosis in children is difficult [14,31-34], because
childhood tuberculosis tends to be paucibacillary and
smear negative. This difficulty can be further compounded
by HIV co-infection.
Less than 1% of patients in our study received influenza
antiviral treatment or influenza vaccination despite being
recommended in national guidelines [35,36]. The associ-
ation between influenza and tuberculosis seen in our study
may be different in settings where influenza vaccination
and antivirals are widely used. In South Africa, while there
are recommendations for annual influenza vaccination,
tuberculosis is not specifically listed as an underlying
co-morbid illness to be targeted for vaccination [37].
Tuberculosis treatment guidelines do not routinely in-
clude influenza vaccination as part of management [15]. A
randomised controlled study of trivalent inactivated influ-
enza vaccine conducted in HIV-infected adults with
CD4+ T cell counts >200 μg/ml in South Africa reported
75% (95% CI 9.2-95.6) efficacy in adults [38]. However, pa-
tients with tuberculosis co-infection or low CD4+ T cell
counts were not included. Although vaccination remains
the most effective method to prevent influenza infection,
tuberculosis infection suppresses immune responses and
thus vaccine effectiveness may be lower in this patient
group. There are no published data on the effectiveness of
influenza vaccination in patients with tuberculosis, par-
ticularly those co-infected with HIV (79% of individuals in
our study).
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we restricted our analysis to patients with tuberculosis
laboratory results at current admission, and our case
definition of laboratory-confirmed tuberculosis included
smear-positive results. As testing for tuberculosis is not
100% sensitive, especially for extra pulmonary tuberculosis
which is common in patients with HIV, we may have mis-
classified a proportion of tuberculosis-positive individuals
as not having tuberculosis; however there is no reason to
suspect that sensitivity would differ between influenza-
positive and -negative patients. The majority of patients
with laboratory-confirmed tuberculosis only had micros-
copy results and it is possible that some may have been in-
fected with mycobacteria other than tuberculosis in a high
HIV prevalence setting such as South Africa. However,
current South African guidelines recommend initiation of
tuberculosis treatment based on smear microscopy results
[11]. Secondly we enrolled acute and chronic cases only at
two enhanced sites and we didn’t systematically test all en-
rolled cases for tuberculosis. The patients tested for tuber-
culosis differed in several characteristics from those not
tested. These differences in enrolment and testing proce-
dures as well as the low proportion of patients tested for
tuberculosis may have introduced potential selection bias
in the population included in the study. Testing all pa-
tients admitted with SRI will improve identification of
tuberculosis cases and the ability to detect significant
differences between groups. We did not collect data on
chest X- ray findings. Availability of data on radiological
changes in the lungs could have strengthened the evi-
dence in support of our hypothesis regarding changes
in the lungs resulting in severe outcome in patients
with underlying tuberculosis co-infected with influenza.
Conclusion
In conclusion, we observed an increased risk of death
among tuberculosis-infected patients co-infected with
influenza with a symptom history of ≥7 days. The poten-
tial public health impact of influenza vaccination among
persons with laboratory-confirmed tuberculosis should
be explored.
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